Neoadjuvant treatment of rectal cancer: Where we are and where we are going  

作　　者：Elísabet González Del Portillo Felipe Couñago Fernando López-Campos 

机构地区：[1]Department of Radiation Oncología,Hospital Universitario La Paz,Madrid 28046,Spain [2]Department of Radiation Oncology,GenesisCare Madrid,Madrid 28010,Spain [3]Department of Radiation Oncology,Hospital Universitario Ramón Y Cajal,Madrid 28034,Spain

出　　处：《World Journal of Clinical Oncology》2024年第7期790-795,共6页世界临床肿瘤学杂志（英文版）

摘　　要：Locally advanced rectal cancer requires a multidisciplinary approach based on total neoadjuvant treatment with radiotherapy(RT)and chemotherapy(ChT),followed by deferred surgery.Currently,alternatives to the standard total neoadjuvant therapy(TNT)are being explored,such as new ChT regimens or the introduction of immunotherapy.With standard TNT,up to a third of patients may achieve a complete pathological response(CPR),potentially avoiding surgery.However,as of now,we lack predictive markers of response that would allow us to define criteria for a conservative organ strategy.The presence of muta-tions,genes,or new imaging tests is helping to define these criteria.An example of this is the diffusion coefficient in the diffusion-weighted sequence of magnetic resonance imaging and the integration of this imaging technique into RT treatment.This allows for the monitoring of the evolution of this coefficient over successive RT sessions,helping to determine which patients will achieve CPR or those who may require intensification of neoadjuvant therapy.

关 键 词：Locally advanced rectal cancer Total neoadyuvant treatment Radiotherapy Biomarker Magnetic resonance imaging Conservative organ strategy Watch and wait 

分 类 号：R730.5[医药卫生—肿瘤]